HSK7653 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

PHASE3CompletedINTERVENTIONAL
Enrollment

476

Participants

Timeline

Start Date

September 29, 2020

Primary Completion Date

January 10, 2022

Study Completion Date

August 8, 2022

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

HSK7653 10 mg Q2W

HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.

DRUG

HSK7653 25 mg Q2W

HSK7653 25 mg (1 tablet) and placebo 5 mg (2 tablets), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.

DRUG

Placebo

Placebo 25 mg (1 tablet) and placebo 5 mg (2 tablets), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.

Trial Locations (2)

100044

Peking University People's Hospital, Beijing

Unknown

Zhujiang Hospital of Southern Medical University, Zhujiang

All Listed Sponsors
lead

Sichuan Haisco Pharmaceutical Group Co., Ltd

INDUSTRY

NCT04556851 - HSK7653 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise | Biotech Hunter | Biotech Hunter